Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Director/PDMR Shareholding

25 Mar 2010 07:00

RNS Number : 1442J
China Real Estate Opportunities PLC
25 March 2010
 



 

 

 

China Real Estate Opportunities plc

 

Directors / PDMR Shareholding

 

In accordance with Rule 17 of the AIM Rules, China Real Estate Opportunities plc ("CREO" or the "Company") announces that on 24 March 2010 it was notified by various directors and a significant shareholder, as detailed below, of share purchases made as part of the recent placing by the Company announced on 23 March 2010. Following the completion of the buy back of 1,500,000 shares for cancellation announced on the same day, the issued share capital of the Company is 48,036,004.

 

Richard Barrett, a director of the Company, notified the Company that on 23 March 2010 he purchased 131,510 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.27 per cent of the issued share capital of the Company.

 

Following the share purchase, Richard Barrett has an interest in 8,955,518 ordinary no par value shares representing 18.64 per cent of the issued share capital of the Company.

 

In addition, the Company was notified by Mr Barrett that members of his family purchased 119,000 ordinary no par value shares representing 0.25 per cent of the issued share capital of the Company. Following the share purchase, members of Mr Barrett's family have an interest in 131,891 ordinary no par value shares representing 0.27 per cent of the issued share capital of the Company.

 

Rory Williams, a director of the Company, notified the Company that on 23 March 2010 he purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Williams has an interest in 175,000 ordinary no par value shares representing 0.36 per cent of the issued share capital of the Company.

 

Richard David, a director of the Company, notified the Company that on 23 March 2010 he purchased 17,500 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.04 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr David has an interest in 30,000 ordinary no par value shares representing 0.06 per cent of the issued share capital of the Company.

 

Ray Horney, a director of the Company, notified the Company that on 23 March 2010 Barclays Wealth Trustees (Guernsey) Limited, acting as Trustee of certain trusts under which Mr Horney and / or members of his family are beneficiaries, purchased 75,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.16 per cent of the issued share capital of the Company.

 

Following the share purchase, Mr Horney has an interest in 2,825,000 ordinary no par value shares representing 5.88 per cent of the issued share capital of the Company.

 

In addition the Company was notified by Mr Horney that a member of his family purchased 45,000 ordinary no par value shares representing 0.09 per cent of the issued share capital of the Company. This purchase represents the total interest in the Company following the share purchase.

 

On the same day, the Company was notified by John Ronan, a significant shareholder of the Company and a 50 per cent shareholder of Treasury Holdings, that a member of his family purchased 55,000 ordinary shares of no par value in the Company at a price of 330p per share. This purchase represents 0.11 per cent and represents their total interest in the Company following the share purchase.

 

 

 

 

 

 

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0) 1273 775 225

 

Sarah Moriarty, Investor Relations

Tel: + 353 1 618 9455

 

 

Matrix Corporate Capital LLP

Paul Fincham, Rob Naylor

Tel: + 44 (0) 20 3206 7000

 

 

Davy

Des Carville

Tel: +353 1 679 6363

 

 

Citigate Dewe Rogerson Limited 

Tom Baldock

Tel: 44 (0) 20 7638 9571

 

 

Murray Consultants

Ed Micheau

Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFDVSISFII
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.